Drug Profile


Alternative Names: KetoNaph; Ketotifen fumarate/naphazoline HCl; Ketotifen fumarate/naphazoline hydrochloride; Ketotifen/naphazoline ophthalmic solution; Naphazoline/ketotifen

Latest Information Update: 27 Nov 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bausch & Lomb
  • Class Antiallergics; Imidazoles; Sedating antihistamines; Small molecules
  • Mechanism of Action Alpha adrenergic receptor agonists; Histamine H1 receptor antagonists; Mast cell stabilisers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Allergic conjunctivitis

Most Recent Events

  • 27 Nov 2015 No recent reports on development identified - Phase-III for Allergic conjunctivitis in USA (Ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top